ClinicalTrials.gg
Active, not recruitingNCT05288998Updated Jan 16, 2026

Intrarenal Microvasculature in ADPKD

An observational study in Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
34
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic — 4 open to participants now, 7 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Mayo Clinic.

Started
2021
with 1 other
Observational
9 of 15
3 open now
Registered
13th of 15
by date

Among the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, this one is one of 2 that started in 2021, is one of 9 observational ones, and was the 13th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

4 of the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the use of Super-resolution ultrasound (SRU) to assess the intrarenal microvasculature in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and healthy volunteers.

Read the detailed description

An intact intrarenal microcirculation is vital to preserving normal kidney function, and microvascular dysfunction, damage, and loss are known to contribute to renal function decline. In ADPKD, extensive vascular remodeling has been proposed to play an important role in its progression. However, microvascular analyses in rodents and humans with ADPKD have been performed ex vivo or in vitro and from kidneys removed at the time of renal failure due to the invasive nature and additional limitations of the currently available techniques. A non-invasive and direct method to assess the intrarenal microvasculature is needed to improve early detection and gauge the progression of microvascular alterations and monitor the success of therapeutic approaches.

Current imaging modalities, such as micro-computed tomography, magnetic resonance imaging, and contrast-enhanced ultrasound, have attempted to provide a non-invasive assessment of the intrarenal microvasculature in pre-clinical models of kidney diseases. However, each of these modalities has important limitations when translating into humans, including high cost, requiring long imaging times, using nephrotoxic contrast agents, radiation exposure, low spatial resolution, and poor reproducibility.

Super-resolution ultrasound (SRU) imaging is among the most rapidly advancing imaging techniques introduced to overcome the limitation of the inherent spatial resolution of ultrasound. With the use of non-nephrotoxic contrast microbubbles to break the diffraction limit of ultrasound, and the introduction of ultrasound localization microscopy which utilizes ultrafast frame rate imaging to reconstruct a super-resolved composite image, SRU has provided a paradigm-shifting tool for structural and functional evaluation of tissue microvasculature. However, in vivo, human imaging, and kidney imaging pose significant organ depth challenges (which results in ultrasound signals with lower signal-to-noise ratio) and physiologic and operator-induced motion (which reduces the available data accumulation time). Our team recently implemented advanced filtering and microbubble localization and tracking techniques to overcome these limitations, which extract only microbubble signals and reliably pinpoint the center of each microbubble from the extracted signals.

The investigators' broad objective is to deploy and evaluate the use of SRU imaging coupled with advanced post-processing techniques to assess the intrarenal microvasculature in patients with early ADPKD and healthy volunteers.

Participants in this study will have a renal ultrasound to determine intrarenal microvascular parameters, and an abdominal MRI to determine the patient's total kidney volume (TKV), and additional vascular parameters. In addition, participants will have a blood and a urine sample collected to determine biomarkers of endothelial function and injury.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease

Keywords

  • ADPKD
  • Intrarenal microvasculature
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with a previous diagnosis of ADPKD that meet the inclusion criteria, and healthy volunteers

Eligibility criteria

Inclusion Criteria (Patients with ADPKD):

  • Male and female subjects 18 - 40 years of age, inclusive
  • Previous diagnosis of ADPKD (based on Ravine et al. criteria)
  • Class 1 according to imaging classification
  • Estimated > 90 mL/min/m2 (CKD-Epi equation)
  • Ability to provide written,

Inclusion Criteria (Healthy Volunteers):

  • Male and female subjects 18 - 40 years of age, inclusive
  • Estimated GFR> 90 mL/min/m2 (CKD-Epi equation)
  • Ability to provide written, informed consent

Exclusion Criteria (Patients with ADPKD):

  • Class 2 according to imaging classification
  • A concomitant systemic disease affecting the kidney (e.g., lupus, or C, amyloidosis)
  • Diabetes mellitus (fasting glucose > 126 mg/dL or treatment with insulin or oral hypoglycemics).
  • Predicted urine protein excretion in urinalysis >1 g/24 hrs.
  • Subjects having to or interference with MRI assessments. [For example ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc.].
  • History of allergic reactions to ultrasound contrast agents
  • High-risk cardiac disease (such as unstable hospital in-patients or ICU patients
  • Patients that are part of an interventional study or are taking tolvaptan
  • Female subjects that are pregnant

Exclusion Criteria (Healthy Volunteers):

  • Family and/or personal history of kidney disease
  • Concomitant systemic disease that may affect the kidney
  • Diabetes mellitus
  • Predicted urine protein excretion in >1 g/24 hrs, and or Abnormal urinalysis
  • Pregnant or lactating women
  • Subjects having contraindications to or interference with MRI assessments. [For example ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc.].
  • History of hypersensitivity allergic reactions to ultrasound contrast agents
  • High risk cardiac disease (such as unstable hospital in-patients or ICU patients
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
34 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with a previous diagnosis of ADPKD

    Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria

  • Healthy Volunteers

    Subjects without a family or personal history of kidney disease or concomitant systemic disorder that might affect the kidney

06

What researchers measure

Primary outcomes

  1. Assessment of intrarenal microvascular density in HV and patients with ADPKD

    Renal vessel density as percentage, determined by SRU.

    Time frame: Baseline

  2. Assessment of intrarenal microvascular flow speed in HV and patients with ADPKD

    Microvascular flow speed (mm/s), determined by SRU.

    Time frame: Baseline

  3. Assessment of intrarenal microvascular perfusion in HV and patients with ADPKD

    Intrarenal perfusion (mm/s), determined by SRU.

    Time frame: Baseline

  4. Assessment of intrarenal tortuosity indices in HV and patients with ADPKD

    Tortuosity indices defined as sum of angles metric (SOAM) (rad/mm), determined by SRU

    Time frame: Baseline

Secondary outcomes

  1. Inter-sonographer variability of the intrarenal microvasculature

    Second US at the same visit performed by a different sonographer, and used to calculate the intraclass correlation coefficient

    Time frame: Baseline

  2. Day-to-day variability of intrarenal microvasculature in healthy volunteers

    A second US within 1-7 days is performed by the same sonographer, to determine the within-person variability for each of the primary outcome measures

    Time frame: Baseline to 7 days

  3. Patient-to-patient variability in patients with ADPKD

    Correlation between primary outcome measures and image class (A, B, C, D and E) as determined by the Image classification.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2022
First posted
Mar 21, 2022
StartActual
Nov 30, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05288998
Lead sponsor
Mayo Clinic
Responsible party
Maria V. Irazabal Mira (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Mar 21, 2022
Start date
Nov 30, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 16, 2026

Study contacts

Maria V Irazabal, M.D., Ph.D
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion